Program

Saturday, September 23, 2017

14:00  – 14:30     Welcome and introduction to the history of and purpose of IFRA

 Lars Klareskog,  Zhanguo Li,  Kazuhiko Yamamoto

Session 1: The good aspects of the situation today and how we arrived here
 

                             Chairs:  Zhanguo Li,  Kazuhiko Yamamoto

 
14:30 – 14:50  From ideas in research to clinical benefits. The long term perspectives
 

Sir  Ravinder Maini, Kennedy Institute, University of Oxford

Session 2: The unresolved clinical and scientific problems of today – and why are they unresolved?
 

                              Chairs:  Josef Smolen, Medical University of Vienna and Codruta Filip PARE/EULAR
 
14:50 – 15:15     Patients’ needs and current scientific approaches to RA; Not always aligned.

 Johan Askling, Karolinska Institutet, Stockholm

15:15 – 15:40     Clinical unresolved problem as seen from “real life” experience and registries

 Merete Hetland, Copenhagen University (to be confirmed)

15:40 – 16:05     Scientific unresolved problems in science

 Chris Buckley, University of Birmingham

16:05 – 16:35     Discussions on need for novel solutions to adess the most important unresolved questions

Discussion led by chairpersons

16:35 – 17.00     Afternoon break with tea and coffee

Session 3 Why do we get RA (1st part); What can we learn from genetic epidemiology and genomics?
 

                              Chairs:  Mike Brenner, Harvard Medical School and Anne Barton, University of Manchester


17:00  – 17:25   “Polygenic burdens on cell-specfic pathways underline the risk of rheumatoid arthritis

Peter Gregersen, Feinstein Institute, New York, NY

17:25 – 17:50     What can studies on environment and life style tell us?

 Saedis Saevarsdottir, Karolinska Institutet, Stockholm

17:50  – 18:15     Combining genetics and epigentic data to define key pathogenic single cell populations in rhematoid  arthritis

 Soumya Raychadhuri, Harvard Medical School, Boston, MA

18:15 – 18:40     Selected abstract: The association between HLA-DRB1 alleles and risk of rheumatoid arthritis is influenced by massive gene-gene interactions

TBA

18:40 – 19:00   Discussions on strategic thinking concerning combinations of cohorts and biomarkers for future design of studies on pathogenesis, prevention and therapy

Discussion introduced and  led by chairpersons


19:00  – > Reception at Aula Medica
 

Sunday, September 24, 2017
 

Session 4: Why do we get RA? (2nd part) The longitudinal course of RA
 

                            Chairs:  Anna Rudin, Gothenburg University and  Mike Holers, University of Colorado at Denver

8:30 – 8:55      From triggering to targeting; the longitudinal course of seropositive RA

 Anca Catrina, Karolinska Institutet, Stockholm

8:55 – 9:20      Autoantibodies and their glycosylation during emergence of RA

 Hans Ulirch Scherer, Leiden University 

9:20 – 9:45      ACPAs, NETs and inflammation. New light on neutrophils

 Mariana Kaplan, NIH, Bethesda, MA

9:45 – 10:20    Pathobiology of Rheumatoid Arthritis: Towards a Molecular Definition and Precision Medicine

Cos Pitzalis, London

10:20 – 10:40 Discussions on strategies to understand the early stages of RA

Discussion introduced and  led by chairpersons


10:40  – 11:05 Morning break with coffee and fruits

Session 5: Why do we get RA (3rd part): The porphytomonas and PAD pathway

                            Chairs: Rene Toes, Leiden University Medical Center and Solbritt Rantapää-Dahlqvist, Umeå
 

10:50 – 11:15  The bacterial way towards RA 1: The porphyromonas and PAD pathway

Karin Lundberg, Karolinska Institutet, Stockholm

11:15 – 11:40  The bacterial way towards RA 2: The Aggregatibacter and hypercitrullination way.

Felipe Andrade, Johns Hopkins, Baltimore, MD

11:40 – 12:05  Role of the microbiome in the pathogenesis of RA

Xuan Zhang, Peking Union Medical College

12:05 – 13:00 Discussions

Discussion introduced and led by chairpersons from session 4 and 5


12:30 – 13:30 Lunch

Session 6: Adaptive vs. Innate immunity and mesenchymal functions as driving
forces in RA

                              Chairs: Andy Cope, King’s College London and Steffen Gay, University of Zürich
 

13:30 – 13:55  Role of specific B and T cells immunity in the initiation of RA

Vivianne Malmström, Karolinska Institutet, Stockholm

13:55 – 14:20  The B cell repertoire in RA

Dan Mueller, University of Minnesota

14:20 – 14:45  Effects of monoclonal antibodies from RA patients on innate functions of synovial cells

Bill Robinson, Stanford University, CA

14:45 – 15:00 Selected abstract: Monoclonal ACPA-IgG feature extensive FAB glycosylation

Kate Lloyd, Karolinska Institutet, Stockholm

15:00 – 15:10 Selected abstract: The mutated RNA splicing protein hnrnp-a3 is a novel autoantigen in systemic rheumatic diseases a link to Warburg effect in RA

Bianka Marklein, Charité University Berlin

15:15 – 15:30 Discussion on the driving forces of RA

Discussion introduced and led by chairpersons

15:30 – 16:00 Afternoon break with coffee

Session 7: adaptive immunity vs innate immunity and mesenchymal functions in RA
(continued)

                            Chairs: Lisa van Baarsen, AMC and Guenter Steiner, Medical University of Vienna
16:00 – 16:25  MFAP5 plays a key role in invasion of FL-like synoviocyte in RA

Huji Xu, The Clinical School of Medicine, Tsinghua University,
The Second Military Medical University, China

16:25 – 16:50 Genetics, T cell specificity and T cell regulation in RA

Jane Buckner, Benaroya Research Institute, Seattle, WA

16:50 – 17:15 How can adaptive immune functions influence stroma cells in RA?

Caroline Ospelt, University of Zürich

17:15 – 17:40 How can we combine understanding of mesenchymal and immune functions in RA?

Ian McInnes, University of Glasgow

17:40 – 17:55 Selected abstract: Machine learning using rheumatoid arthritis synovial gene expression  data defines histologic features that correlate with systemic inflammation and autoantibodies

Dana Orange, Rockefeller University

17:55– 18:15 Discussions on adaptive immunity vs innate immunity and mesenchymal functions in RA

Discussion introduced and led by chairpersons
 

18:15 – 19:30 Posters, discussion clubs and other informal meetings with wine and
cheese

Monday September 25th

Session 8: The systemic features of RA; focus on pain and cognition

                        Chairs : Caroline Grönwall, KI and Ger Pruijn, Radbound University Medical Centre

8:30 - 8:55  Introduction to post-translational modifications

Ger Pruijn, Radbound University Medical Centre

8:55 – 9:20 The Role of PADs in RA

Hirofumi Shoda, University of Tokyo

9:20 – 9:35 Role of osteoclasts in bone inflammation

Hiroshi Takayanagi, University of Tokyo

9:35 – 9:50 Selected abstract: RA-associaited antibodies targeting post-translational modification have different osteoclastogenesis potential

Akilan Krishnamurthy, Karolinska Institutet, Stockholm

9:50 – 10:15 Discussions

Discussion introduced and led by chairpersons

10:15 – 10:40 Morning break with coffee.

Session 9: Can we prevent RA?

      Chairs : Dimitirs Boupmas, Biomedical REsearch Foundation Acadamy of Athens and Lars Alfredsson, KI

10:45 – 11:05  Trials for prevention: How to do it?

Tom Huizinga, Univeristy of Leiden

11:05 – 11:30  How to understand and measure “subjective symptoms” that matter for the patient ?

Karim Raza, University of Birmingham

11:30 – 11:55 Therapy is not only medicines. How to accomplish and measure effects of change of life style and eviroment?

Jill Norris, University of Colorado at Denver

11:55 – 12:20 How can we prevent RA?

Discussion introduced and led by chairpersons


12:20 – 13:45 Lunch

Session 10 Mechanisms of pain in ra

Chairs: Christina Opava, KI and Alsion Kent PARE

13:45 - 14:10  Pain and cognition in RA, Which are the central mechanisms?

Georg Schett, Erlangen University Clinic

14:10 – 14:35 Longitudinal development of pain in RA

Jon Lampa, Karolinska Institutet, Stockholm

14:35 – 15:00  Antibody-mediated pain

Camilla Svensson, Karolinska Institutet, Stockholm


15:00 – 15:30 Afternoon break with coffee

Session 11: New ways of understanding the individual’s most urgent problems and how they change over time; What role for e-health

Chairs: Gerd Burmester, Charité, Berlin and TBA

15:30 – 15:55 Emerging oppuortunities for digital health research in RA

Will Dixon, University of Manchester

15:55 – 16:20 Meeting the patients early with an app: What options and what obstacles?

Sofia Ernestam, Karolinska Institutet, Stockholm

16:20 – 17:05 What will happen with “patient reported outcomes” in the future?

Tore Kvien, Oslo University

17:05 – 17:30 Discussions

Discussion introduced and led by chairpersonsfrom session 10 and 11

18:30 Leave for City Hall

Tuesday, September 26th

Session 12: New targets for prevention and therapy – adaptive and innate immunity again

Chairs:  Marc Feldmann, University of Oxford and Ronald van Vollenhoven, KI and University of Amsterdam

8:30 – 8:55  Tolerance therapies – will they become real?

Ranjeny Thomas, University of Queensland

8:55 – 9:20  Tolerizing T cells

Rikard Holmdahl, Karolinska Institutet

9:20 – 9:45  New smart trial designs

John Isaacs, Newcastle University

9.45 - 10:15 Morning break with coffee

Session 13 Future trials for prevention and curative treatments; Which strategies?

           Chairs: Lars Klareskog, KI, Marc Feldmann, University of Oxford and Ronald van Vollenhoven, KI and University of Amsterdam

10:15 – 10:40 Bioelectronic Medicine: Technology Targeting Molecular Mechansims for Therapy

Peder Olofsson, Karolinska Institutet, Stockholm


Discussions woth representatives from academia, industry and health care led by the chairpersons
 

10:45 – 12:15 Perspectives from industry, academia and health care; How should we combine our efforts to make new generation of curative and preventive therapies real?

Confirmed guests: Anish Suri, Janssen, Aaron Winkler, Pfizer, Steven Nadler, BMS

12:15 – 12:40 Clinicla and basic research of RA in China - challenge and catch up

Zhanguo Li, Beijing University


 

12:40 Lunch and Departures

More detalis will be added shortly